123 related articles for article (PubMed ID: 12917021)
1. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
[TBL] [Abstract][Full Text] [Related]
2. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
[TBL] [Abstract][Full Text] [Related]
3. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
5. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
6. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
7. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.
Pianetti S; Guo S; Kavanagh KT; Sonenshein GE
Cancer Res; 2002 Feb; 62(3):652-5. PubMed ID: 11830514
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Masuda M; Suzui M; Lim JT; Weinstein IB
Clin Cancer Res; 2003 Aug; 9(9):3486-91. PubMed ID: 12960141
[TBL] [Abstract][Full Text] [Related]
13. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
14. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.
Zhou BP; Liao Y; Xia W; Spohn B; Lee MH; Hung MC
Nat Cell Biol; 2001 Mar; 3(3):245-52. PubMed ID: 11231573
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
19. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
Sastre-Garau X; Genin P; Rousseau A; Al Ghuzlan A; Nicolas A; Fréneaux P; Rosty C; Sigal-Zafrani B; Couturier J; Thiery JP; Magdelénat H; Vincent-Salomon A
Histopathology; 2004 Aug; 45(2):142-7. PubMed ID: 15279632
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM; Basso A; Averbuch SD; Rosen N
Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
